Ipragliflozin, a sodium–glucose cotransporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: A randomized clinical trialHideka Inoue, Hiroshi Maegawa, Katsutaro Morino et al.|Journal of Diabetes Investigation|2018Cited by 62
Smoking, Smoking Cessation, and Measures of Subclinical Atherosclerosis in Multiple Vascular Beds in Japanese MenTakashi Hisamatsu, Keiko Kondo, Kenichi Mitsunami et al.|Journal of the American Heart Association|2016Cited by 55
Lifetime cigarette smoking is associated with abdominal obesity in a community-based sample of Japanese men: The Shiga Epidemiological Study of Subclinical Atherosclerosis (SESSA)Akira Fujiyoshi, Hirotsugu Ueshima, Katsuyuki Miura et al.|Preventive Medicine Reports|2016Cited by 48
Metabolic changes induced by dapagliflozin, an SGLT2 inhibitor, in Japanese patients with type 2 diabetes treated by oral anti-diabetic agents: A randomized, clinical trialKayo Horibe, Hiroshi Maegawa, Katsutaro Morino et al.|Diabetes Research and Clinical Practice|2022Cited by 27
Associations of serum LDL particle concentration with carotid intima-media thickness and coronary artery calcificationMaryam Zaid, Aya Higashiyama, Katsuyuki Miura et al.|Journal of clinical lipidology|2016Cited by 19